Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
8 hedge funds and large institutions have $4.37M invested in Proshares UltraPro NASDAQ Biotechnology in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
79,950% more call options, than puts
Call options by funds: $1.6M | Put options by funds: $2K
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
300% more funds holding
Funds holding: 2 → 8 (+6)
112% more capital invested
Capital invested by funds: $2.06M → $4.37M (+$2.31M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$1.35M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.19M |
| 3 |
Jane Street
New York
|
+$596K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$295K |
| 5 |
CT
CMT Trading
Chicago,
Illinois
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAMS
Bellevue Asset Management (Switzerland)
Kuesnacht,
Switzerland
|
-$2.04M |
UBIO Hedge Fund Activity: Q4 2015 in Review
8 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q4 2015, worth a combined $4.37M — up 112% from $2.06M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new UBIO positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $1.35M. The largest seller was Bellevue Asset Management (Switzerland), exiting entirely with an estimated $2.04M sold.
- 8 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q4 2015, up from 2 in Q3 2015.
- Funds reported $4.37M of Proshares UltraPro NASDAQ Biotechnology stock for Q4 2015, up 112% quarter-over-quarter.
- 7 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q4 2015 and 1 closed out, a net change of +6 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q4 2015 was Virtu Financial, an estimated $1.35M added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q4 2015 was Bellevue Asset Management (Switzerland), an estimated $2.04M sold.
Based on aggregated 13F filings for Q4 2015.